Schering Aktiengesellschaft

Other

Novartis Ag

Bayer Schering Pharma Ag

Mivenion Gmbh

Morphosys Ag

Visen Medical, Inc.

Freie Universitat Berlin

Epiios Therapeutics Gmbh

Icd-therapeutics Gmbh

Ic Discovery Gmbh

Bundesrepublik Deutschland, Vertr. D.d. Bundes- Ministerium F. Wirtschaft- Und Technologie, Dieses Vertr. D.d. Präs. D. Phys.-techn. Bundesanstalt

Michael Schirner

Werner Skuballa

Ulrich Klar

Wolfgang Schwede

Bernd Buchmann

Kai Licha

Pascal Furet

Andreas Huth

Paul William Manley

Guido Bold

Dieter Seidelmann

Eckhard Ottow

Karl-Heinz Thierauch

Andreas Menrad

Jeanette Marjorie Wood

Axel Vater

Rainer Haag

Jürgen Mestan

Martin Krüger

Stefano Ferrari

Marie Weinhart

Florian Paulus

Malte Bahner

Sonja Vollmer

Pia Welker

Bodo Brocks

Jose Brüggen

Cornelia Hanel

Stefanie Urlinger

Martin Pessel

Yinan Zhong

Mathias Dimde

Daniel Braatz

The present invention relates to novel dendrimer conjugates, methods for their preparation and their use for treatment of diseases. The invention discloses a new method for the delivery of dendrimer conjugates with therapeutically active molecules into the cell by utilizing transmembrane solute carrier proteins enabling uptake of the inventive dendrimer conjugates. Particular subject-matter of the present invention is a conjugate of the formula E-[G-L-D(OSOM)], wherein E is a therapeutic or diagnostic effector molecule, wherein D(OSOM)is a dendrimer D carrying a number n of sulfate groups OSOM, wherein the number n of sulfate groups is selected from 6 to 96, wherein M is a cationic inorganic or organic counter ion to the anionic sulfate group, wherein L is a linker or spacer between D and E, wherein G is a connecting functional group forming the attachment between L and E, and wherein m is an integer from 1 to 20.

Therapeutic conjugates with sulfated dendrimers for intracellular targeting

The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations.

Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis

The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.

Optical imaging of rheumatoid arthritis

The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.

Anthranilic acid amides and the use thereof as medicaments

Disclosed are epothilone compounds of formula I,which are useful as pharmaceutical compounds for treating, for example, malignant tumors and chronic inflammatory diseases and are useful in anti-angiogenesis therapy.

Epothilon derivatives, method for the production and the use thereof as pharmaceuticals

A compund of formula I, an epothilone derivative, its method of preparation, and use as a pharmaceutical agent in treating malignant tumors

16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use

The invention relates to novel epothilone derivatives of general formula (I), wherein R means a halogen atom, especially a fluorine or chlorine atom, and the remaining substituents have the meanings given in the description. The novel compounds are suitable for producing medicaments.

16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use

Growing community of inventors

Berlin, Germany

Michael Schirner